monoclonal antibodies

Selbyville, Delaware, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Global antibody therapy market value projected to cross USD 445 billion by 2028, according to a new research report by Global Market Insights Inc. Growing number of innovative…

–  Growing body of evidence validates Vir’s approach of targeting a highly conserved region of the spike protein – – Together with recent pseudo- and live virus results, additional preclinical data reinforce sotrovimab retains in vitro…

JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its…

FDA laboratory testing confirms SAB-185 neutralizes Omicronand other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue to show broad neutralization to viral…

 – Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron – – Data to be confirmed by further in vitro…

– US government contracts for approximately $1 billion1 (USD) now in place to purchase sotrovimab, further expanding access nationwide – – This brings the total number of doses secured through binding agreements to more than 750,000…

SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in the Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial…

as an indirect strategy. in the shape of spikes enable it to attach itself to human cells and enter the cells to cause infection. The two monoclonal antibodies called casirivimab and imdevimabin REGEN-COV drug produced by Regeneron bind…

– Opinion based on the EMA’s Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 – – EU member states can use the CHMP positive scientific opinion…

– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 – – Review will support a formal Marketing Authorization…